Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 8/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.40 |
| ▸ | MERTK | Q12866 | 6/20 | 0.40 |
| ▸ | AXL | P30530 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080203 | 0.92 | ACVRL1 (0.42) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL14313354 | 0.92 | ACVRL1 (0.44) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL5081049 | 0.91 | ACVRL1 (0.44) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL14314294 | 0.90 | MERTK (0.42) | TYRO3ACVRL1MERTKAXLRIPK1 | |
| SCHEMBL14531768 | 0.90 | TYRO3 (0.42) | TYRO3ACVRL1MERTKAXLRIPK1 | |
| SCHEMBL14898479 | 0.90 | TYRO3 (0.44) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL14312988 | 0.89 | TYRO3 (0.48) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL14313195 | 0.89 | MERTK (0.47) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL14327037 | 0.88 | TYRO3 (0.43) | TYRO3ACVRL1MERTKAXL | |
| SCHEMBL14312385 | 0.88 | TYRO3 (0.49) | TYRO3MERTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | TYRO3 345/4885ACVRL1 336/4885MERTK 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.